🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 48 of 55

  1. Tislelizumab

    BeiGene

    Cervical Cancer

    phase 2 mab completed

    1 trial

  2. Tislelizumab

    The First People's Hospital of Lianyungang

    Biliary Tract Tumor

    phase 2 small molecule active

    1 trial

  3. Tislelizumab

    The First People's Hospital of Lianyungang

    Bladder Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  4. Tislelizumab

    The First People's Hospital of Lianyungang

    HER2-positive or Mutated Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  5. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  6. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  7. Tislelizumab (BGB-A317)

    BEONE MEDICINES AUS PTY LTD

    MSI-H/dMMR Solid Tumors

    phase 2 small molecule active

    1 trial

  8. Tislelizumab combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  9. TmBU conditioning Regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  10. Tolecizumab (PCSK9 Inhibitor)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colon Adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. Tolinapant, Tolinapant

    Taiho Pharma Netherlands B.V.

    Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy

    phase 2 small molecule active

    1 trial

  12. Toripalimab

    The First People's Hospital of Lianyungang

    Adenocarcinoma of the Stomach

    phase 2 small molecule active

    1 trial

  13. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Triple-Negative Breast Cancer (TNBC)

    phase 2 small molecule active

    1 trial

  14. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tracheal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  15. Toripalimab

    Coherus Oncology

    Sinonasal Cancer

    phase 2 small molecule active

    1 trial

  16. Toripalimab

    Coherus Oncology

    Localized Colon Carcinoma

    phase 2 small molecule active

    1 trial

  17. Toripalimab

    Coherus Oncology

    Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

    phase 2 small molecule active

    1 trial

  18. Toripalimab

    The First People's Hospital of Lianyungang

    Urinary Bladder Neoplasms

    phase 2 small molecule active

    1 trial

  19. Toripalimab

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  20. Toripalimab

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule terminated

    1 trial

  21. Toripalimab

    The First People's Hospital of Lianyungang

    Pancreatic Carcinoma

    phase 2 small molecule active

    1 trial

  22. Toripalimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  23. Toripalimab

    The First People's Hospital of Lianyungang

    Locally Advanced Colon Cancer

    phase 2 small molecule active

    1 trial

  24. Toripalimab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  25. Toripalimab

    Yongchang Zhang

    Advanced Non Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  26. Toripalimab + Chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Thymic Epithelial Tumor

    phase 2 small molecule active

    1 trial

  27. Toripalimab + Chemotherapy

    Coherus Oncology

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  28. Toripalimab+Nedaplatin+Albumin Paclitaxel

    The First People's Hospital of Lianyungang

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  29. Toripalimab-tpzi

    Coherus Oncology

    Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  30. Total Neoadjuvant Treatment

    The First People's Hospital of Lianyungang

    Biliary Tract Neoplasms

    phase 2 small molecule active

    1 trial

  31. Tovorafenib, Tovorafenib

    Lacuna Pharma Pty Ltd

    RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors in pediatric patients

    phase 2 small molecule active

    1 trial

  32. Trametinib (GSK1120212)

    ADIAL PHARMACEUTICALS, INC.

    Melanoma

    phase 2 small molecule completed

    1 trial

  33. TransCon IL-2 ß/ү, TransCon TLR7/8 Agonist, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

    phase 2 small molecule active

    1 trial

  34. TransCon TLR7/8 Agonist, TransCon IL-2 ß/ү, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  35. Transarterial chemoembolization

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unresectable Colorectal Cancer

    phase 2 other active

    1 trial

  36. Trastuzumab

    United Therapeutics Europe Ltd

    Metastatic Colon Adenocarcinoma

    phase 2 mab terminated

    1 trial

  37. Trastuzumab

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  38. Trastuzumab

    KAZIA THERAPEUTICS LTD

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  39. Trastuzumab

    United Therapeutics Europe Ltd

    Metastatic Colorectal Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  40. Trastuzumab deruxtecan

    AstraZeneca

    Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

    phase 2 small molecule active

    1 trial

  41. Trastuzumab in Combination with TS-ONE and cisplatin

    Hospital Authority, Hong Kong

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  42. Trilaciclib

    The First People's Hospital of Lianyungang

    Advanced Squamous Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  43. Trilaciclib

    The First People's Hospital of Lianyungang

    Osteosarcoma

    phase 2 small molecule active

    1 trial

  44. Trilaciclib and Sacituzumab Tirumotecan

    The First People's Hospital of Lianyungang

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 2 small molecule active

    1 trial

  45. Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  46. Trodelvy 200 mg powder for concentrate for solution for infusion, Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  47. Tumor Intiltrating Lymphocytes (TIL) – VHIO, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, Melanoma Tumor Intiltrating Lymphocytes (TIL) – NKI, Fludarabine - PCH 25 mg/ml, concentraat voor oplossing voor intraveneuze infusie of injectie, ANV419, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Genoxal 1.000 mg polvo para solución inyectable y para perfusión, PROLEUKIN, 18x106 UI polvo para solución inyectable o para perfusión, PROLEUKIN®

    The George Institute

    Advanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

    phase 2 small molecule active

    1 trial

  48. Tumor infiltrating lymphocytes (TIL) LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.